Sir,

Pemphigus vulgaris (PV), a chronic autoimmune blistering disease, is frequently associated with high morbidity and mortality. Currently, there are several treatment options for PV with variable results. Etanercept (ETN), a recombinant fusion protein of the extracellular ligand-binding domain of human 75-kDa tumor necrosis factor (TNF) receptor and the FC portion of human IgG1, acts as a competitive inhibitor of TNF and has several clinical label and off-label indications, the latter include PV.

We included five patients with PV treated with ETN-methotrexate (ETN-MTX). Patients' characteristics are summarized in [Table 1](#T1){ref-type="table"}. The patients had been treated for at least 4 months with different treatment options like prednisone plus azathioprine, cyclophosphamide, mycophenolate mofetil or even MTX, with partial remission and relapse.

###### 

Characteristics of the patients studied
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The patients were treated with ETN (25 mg twice weekly) and MTX (12.5-15 mg weekly) during 16 weeks to achieve disease control (only one patient \[No. 2\] required 20 weeks of treatment). All patients, at the end of the treatment, received prednisone ≤20 mg/day for 2 months and then tapered and maintaining MTX unmodified. The mean follow-up was 24.33 ± 6.4 months. No adverse events, such as hepatotoxicity, myelosuppression, infections, or malignancies, were evident. The only adverse event reported was injection site reaction (patient 1 and 4).

We determined that ETN-MTX is effective in treating recalcitrant PV with long-term follow-up with no evidence of relapse. Few studies describe the effectiveness of ETN for PV;\[[@ref1][@ref2][@ref3][@ref4]\] however, this is the first to determine the effectiveness of ETN-MTX on recalcitrant PV with an excellent clinical response that has been sustained for 24 months.
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